

**Form 51-102F3**  
***Material Change Report***

**1. Name and Address of Company**

**Enttheon Biomedical Corp.**  
Suite 720 - 999 W Broadway Street  
Vancouver, BC  
V5Z 1K5  
(the "Company")

**2. Dates of Material Change(s)**

February 28, 2023

**3. News Release(s)**

News release was issued on March 1, 2023 and disseminated via Stockwatch pursuant to section 7.1 of National Instrument 51-102.

**4. Summaries of Material Changes**

The Company announces that Ruth Chun has resigned as a director of the Company effective February 28, 2023.

**5. Full Description of Material Changes**

News Release dated March 2, 2023– See Schedule "A".

**6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**7. Omitted Information**

No information has been omitted.

**8. Executive Officer**

Mr. Timothy Ko, President, CEO and Director of the Company, is knowledgeable about the material change contained herein and may be reached at (604) 562-3932.

**9. Date of Report**

This report is dated March 3, 2023

## **Entheon Announces Resignation of Ruth Chun**

Vancouver, British Columbia— (March 1, 2023) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("**Entheon**" or the "**Company**") announces that Ruth Chun has resigned as a director of the Company effective February 28, 2023. The Company benefitted from Ms. Chun's expertise in corporate and legal matters and would like to thank her for her contributions and services as a director of Entheon.

"I want to thank Ms. Chun for all of her hard work over the past two years. Management and the Board of Directors appreciated her dedication to the company and wish her well on her future endeavours."

Timothy Ko – CEO and Director

### **About Entheon Biomedical Corp.**

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

**For more information, please contact the Company at:**

|  |            |       |
|--|------------|-------|
| Entheon  | Biomedical | Corp. |
| Timothy  | Ko,        | CEO   |
| <a href="mailto:timothy@entheonbiomedical.com">timothy@entheonbiomedical.com</a> |            |       |
| <a href="https://entheonbiomedical.com/">https://entheonbiomedical.com/</a> .    |            |       |

*The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.*